34 results about "Dry powder inhalation" patented technology

The invention provides a medication monitoring device and a medication monitoring method, relates to the field of medical apparatuses and instruments, and solves the technical problem that whether a capsule rotates to release medicines or not is difficult to monitor in a capsule type dry powder inhalation used in a transversely placed inhaler. The medication monitoring device comprises a shell and a photoelectric sensor, the photoelectric sensor is arranged on the shell, and a light path of the photoelectric sensor is configured to penetrate through the air inlet of the inhaler and the medicine bin, so that the rotation state of the capsule in the medicine bin is judged by detecting the change of the light path; the photoelectric sensor and the air inlet of the inhaler are arranged in a spaced mode in space so as to allow the inlet air flow to pass through. The rotation state of the capsule in the medicine bin is judged by detecting the change of the light path, whether the capsule rotates or not can be directly monitored, the problems that in the prior art, whether the capsule rotates or not cannot be known, and medicine taking failure caused by improper posture of the capsule cannot be judged are solved, effectiveness of medicine taking monitoring is ensured, and medicine taking guidance is facilitated.

The invention relates to the technical field of powder inhalation inhalers, in particular to a monitoring device for a capsule type powder inhalation inhaler. The monitoring device comprises a shell, the inhaler is installed on the shell, the shell is provided with a photoelectric sensor, the photoelectric sensor comprises an emitter and a receiver, the emitter and the receiver are arranged at the positions of two air inlets of the inhaler respectively, a set distance is reserved between the emitter and the air inlets, and a set distance is reserved between the receiver and the air inlets. The centers of the emitter, the receiver, the air inlet and the inhaler are positioned on the same straight line; the distance between the emitter and the air inlet and the distance between the receiver and the air inlet range from 0.99 mm to 8 mm. According to the invention, the airflow velocity can be indirectly obtained by directly monitoring the rotation state of the capsule, and meanwhile, the interference to normal air intake of the inhaler is reduced, so that the reliability and effectiveness of medication monitoring are improved.

The present invention relates to carrier particles for dry powder formulations for inhalation and a process for preparing the same.

A dry powder inhalation system includes a breath detection device, a drug delivery device, and a computing device. The breath detection device is configured to monitor the breathing state of an animal and transmit the signals of the breathing state. The drug delivery device is configured to deliver the dry powder orally or nasally to the lungs of the animal. The computing device is configured to receive the signals of the breathing state, evaluate a stress state of the animal, predict a breathing cycle of the animal, and control the drug delivery device to release the dry powder during a non-stressed inhalation period for the animal to inhale the dry powder autonomously. A dry powder administration method is also disclosed.

This invention relates to the field of filling equipment technology and discloses a storage-type automated filling equipment for dry powder inhalers. The equipment includes a workbench, a frame fixedly mounted on the top of the workbench, a mounting frame mounted on the top of the frame, a support frame fixedly mounted on the top of the mounting frame, and a drive motor mounted on the top of the support frame. The output shaft of the drive motor passes through the interior of the mounting frame and is fitted with a track. A rotating rod is rotatably mounted inside the mounting frame, and the bottom of the rotating rod passes through the interior of the mounting frame and is fixedly fitted with a rotating wheel. In this invention, a camera, a rotating wheel, a positioning wheel, a drive motor, and an electric push rod work together. The electric push rod pushes the positioning wheel to clamp the filling bottle, the drive motor drives the rotating wheel to rotate and adjust the bottle angle, and the camera identifies and positions the bottle in real time, accurately correcting the bottle placement to ensure precise alignment between the filling nozzle and the discharge port of the filling component.

The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition loaded in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.

The invention discloses a carrier-free mometasone furoate dry powder inhaler and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the carrier-free mometasone furoate dry powder inhaler comprises mometasone furoate and an excipient, and the preparation method comprises the following steps: firstly, mixing mometasone furoate and the excipient according to a mass ratio of 10: 90-90: 10, transferring into a beaker, adding a proper amount of water, stirring, and carrying out suction filtration; adding an ethanol-water mixed solution, and stirring until solids are completely dissolved to obtain a spray-dried raw material solution; carrying out spray drying on the spray drying raw material solution by adopting a spray dryer, and collecting a product after drying to obtain microspheres, namely the carrier-free mometasone furoate dry powder inhalant. According to the carrier-free mometasone furoate dry powder inhalant, lactose does not need to be used as a carrier, the allergy risk possibly caused by lactose is avoided, meanwhile, a microsphere structure with the surface wrinkled is formed through a spray drying technology, the medicine mainly exists in an amorphous state, and the dispersity and solubility of mometasone furoate are remarkably improved.

The invention relates to a single-dose type dry powder administration device, and belongs to the field of dry powder inhalers. Comprising a device body and a medicine bin assembly. Wherein the medicine bin assembly comprises a medicine bin main body, a medicine bin cover, a sealing film and a gasket, the medicine bin main body is used for storing medicine powder, an empty groove is formed in the medicine bin cover, the sealing film is packaged and fixed on the medicine bin cover, and the medicine bin main body and the medicine bin cover are fixed through a buckle; the gasket is arranged between the medicine bin body and the medicine bin cover. By means of the structure, the packaging piece and the medicine powder are separated, the situation that in the packaging process, due to the temperature, the biomacromolecule medicine powder loses activity is avoided, and medicine with the strict requirement for the storage temperature can be treated through a dry powder inhalation means.

A dry drug powder inhalation device comprises a breath detection device, a drug delivery device and a computer device. The respiration detection device is configured to monitor a respiration state of an animal and transmit a plurality of respiration state signals. The administration device is configured to orally or nasally apply a dry drug powder to the lungs of the animal. The computer device is configured to receive the breathing status signal, assess a tense status of the animal, predict a breathing cycle of the animal, and control the administration device to release dry drug powder for autonomous inhalation by the animal during non-tense inspiration. Also disclosed herein are methods of drug dry powder administration. The medicine dry powder inhalation device can improve effective administration of medicine dry powder to bronchus or lungs through the trachea of an animal.

The present invention provides: a nicotine dry powder inhalation composition; and a method for producing same. The nicotine dry powder inhalation composition comprises nicotine powder and flavor powder, the composition being characterized in that: the nicotine powder includes a nicotine or nicotine salt, an amino acid, and an excipient; the flavor powder includes a flavor and an excipient; and the nicotine content is less than 0.5 wt% with respect to the total dry powder composition.

The application discloses a preparation method of inhalation budesonide superfine crystal with adjustable particle size; the preparation method comprises the following steps: (1) dispersing and dropping budesonide solution A into a deep cold environment with a temperature of-100 to-200 DEG C, and rapidly solidifying the liquid drops into spherical composite particles; (2) under the action of stirring, adding the solidified spherical composite particles in the step (1) into an aqueous solution containing an emulsifier with a temperature of-5 DEG C to 15 DEG C, and obtaining budesonide superfine crystal. The particle size of the budesonide superfine crystal can be effectively adjusted by changing the concentration of the solution A; the obtained superfine crystal product is an ellipsoid with uniform particle size, a roundness value of 0.6 to 1.0, a CV value of 20% to 30%, an average particle size range of 1 to 10 microns, and a unique crystal form; the product is suitable for being developed into an inhalation administration dosage form, especially a dry powder inhalation agent; the process is stable, does not need a post-granulation process such as airflow crushing, is energy-saving and environment-friendly, and can realize large-scale preparation and production.

1. The name of the design product: dry powder inhaler. 2. The use of the design product: the design product is used to assist dry powder inhalation of medicine. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition filled in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a drug product or a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.

The invention discloses a rifapentine capsule type dry powder inhaler and a preparation method thereof, the capsule type dry powder inhaler comprises a capsule shell and a capsule content, and the capsule content comprises the following components in parts by weight: 1 part of rifapentine, 1-30 parts of a carrier and 0.01-1 part of a flow aid. According to the invention, micronized drug bulk drugs and appropriate excipients are in the form of capsules, and atomized drugs are actively inhaled into the lungs by a patient through a specially-made dry powder inhalation device. The delivery efficiency of the preparation is high, and the lung deposition rate is high; the particle size of the preparation and the stability of the preparation are high, and the compatibility between raw materials and auxiliary materials is good. The rifapentine capsule type dry powder inhaler disclosed by the invention has no gastrointestinal tract degradation effect and no liver first-pass effect, the medicine can directly act on the lung, the absorption is quick, and the effect is quick after administration; meanwhile, local administration is realized, the dosage is obviously reduced, and toxic and side effects are small. The preparation method disclosed by the invention is simple and easy to implement, has no too high requirements on technical equipment, and is suitable for domestic industrial production.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Dry powder inhaler systems for pulmonary delivery of pharmaceuticals are disclosed.

The present application relates to the use of baicalein, in particular to a kind of asthma-relieving pharmaceutical composition and the application of preparation of inhalation asthma-relieving medicine.The composition is baicalein and auxiliary material with mass ratio of 1:0.3-3, wherein the auxiliary material is one or several of leucine, mannitol, glycine, alanine, proline, isoleucine, threonine, aspartic acid, arginine, methionine, anhydrous lactose, glucose, D-sorbitol.The composition is applied to the preparation of inhalation asthma-relieving medicine.The baicalein nanocrystal dry powder inhaler prepared by the present application has the characteristics of high fine particle fraction (FPF), storage stability, small irritation, etc.The present application first prepares baicalein into dry powder inhaler with nanocrystal as intermediate, and the preparation process of the preparation is characterized by good repeatability.The advantages of the target preparation are proved by a series of in-vivo and in-vitro means.

The present invention provides a stick for a dry powder inhaler comprising a filter portion, a capsule portion, and a tube portion, wherein the capsule portion contains nicotine dry powder, and one or more of the filter portion and the tube portion contain a cough suppressant, and a dry powder inhaler comprising the same.

This invention relates to a method of treatment of asthma comprising a pro re nata (PRN) administration of a fixed-dose dry powder inhalation composition comprising fluticasone propionate and albuterol sulfate as a rescue medication in patients, wherein the fluticasone propionate is administered at a delivered dose of 22-59 mcg per inhalation and the albuterol sulfate is administered at a delivered dose of 92-124 mcg per inhalation, and wherein the treatment provides an improved baseline-adjusted postdose forced expiratory volume in one second (FEV1) area under the effect curve from time zero to 6 hours (AUEC0-6h) when compared to fluticasone propionate treatment and an improved baseline-adjusted trough FEV1 when compared to albuterol sulfate treatment.

The invention relates to a ciprofloxacin dry powder inhalation particle, the dry powder inhalation particle comprises 60-95% by weight of ciprofloxacin hydrochloride and a pharmaceutically acceptable carrier, the mass median aerodynamic diameter (MMAD) of the dry powder inhalation particle is 1-5 [mu] m, and the geometric particle size distribution is that D10 is less than or equal to 2.0 [mu] m, D50 is less than or equal to 4.5 [mu] m, and D90 is less than or equal to 8.0 [mu] m. The dry powder inhalation particle can target high-concentration deposition of a lung infection part, the bioavailability is remarkably improved, and risks of renal toxicity, ototoxicity, drug resistance and the like are reduced.

Methods for treating or preventing a pulmonary fungal infection in a recipient of, for example, a lung transplant are disclosed.

The invention discloses a dry powder inhaler of a GLP-1 receptor stimulant and a preparation method and application of the dry powder inhaler, and belongs to the technical field of biological medicine, the dry powder inhaler comprises the following raw materials in percentage by mass: 0.01%-10% of GLP-1 drugs, 10%-99% of carriers and 0-80% of auxiliary materials, the carrier is at least two of first lactose, second lactose, mannitol, xylitol, cyclodextrin, a cyclodextrin derivative, trehalose, trehalose hydrate, dipalmitoyl lecithin, distearoyl phosphatidylcholine, glucose, amino acid and an amino acid derivative, and the prepared dry powder inhalant of the GLP-1 receptor agonist is used for pulmonary administration, has the advantages of high bioavailability and high bioavailability, and can be used for preparing the dry powder inhalant of the GLP-1 receptor agonist. The medicine can be directly inhaled into the end bronchus or alveolus of the respiratory tract in the form of particles and absorbed by the lung, and the medicine can be rapidly absorbed into blood by utilizing the characteristics of short pulmonary circulation path, thin pulmonary artery wall, multiple pulmonary vessel branches and the like, so that the medicine takes effect more rapidly.

The invention discloses a lung protection function exosome based on resveratrol-astragalus membranaceus-ginseng induction, an inhalation preparation and application, and belongs to the technical field of biology. The exosome is obtained by inducing lung fibroblasts by active ingredients containing resveratrol, an astragalus extract and a ginseng extract and then secreting the lung fibroblasts; wherein the content of astragaloside in the astragalus extract is not less than 2.0%, and the total content of ginsenoside Rg1 and Rb1 in the ginseng extract is not less than 5.0%. The invention also provides a dry powder inhalant or an aerosol inhalation solution containing the exosome. The exosome and the preparation thereof play a lung protection role through multiple mechanisms such as inflammation regulation and control, oxidative stress resistance and repair promotion, can be used for preventing and / or treating various lung injury diseases such as acute lung injury and pneumonia, and have the advantages of good biocompatibility and strong targeting property.

The present invention relates to a method of treating asthma comprising administering as rescue medication a fixed-dose dry powder inhalation composition comprising fluticasone propionate and salbutamol sulfate in patients aged > 4 years on an as-needed (PRN) basis, wherein the fluticasone propionate is administered at a delivered dose of 22-59 micrograms per inhalation, the salbutamol sulfate is administered at a delivered dose of 92-124 micrograms per inhalation, and the treatment provides one or more of: an extended time to first severe clinical asthma exacerbation compared to salbutamol sulfate rescue treatment, a reduced total annualized systemic corticosteroid (SCS) exposure compared to salbutamol sulfate rescue treatment, a reduced annualized rate of severe clinical asthma exacerbations compared to salbutamol sulfate rescue treatment. Also provided is a fixed-dose dry powder inhalation composition and a dry powder inhaler for use in performing the method of the invention.

The present invention relates to a method of treating asthma, said method comprising the treatment of asthma at an age of > = 4 years to lt; a fixed dose of a dry powder inhalation composition comprising fluticasone propionate and salbutamol sulfate is administered as an emergency drug on demand (PRN) for a 18-year-old patient. Fixed dose dry powder inhalation compositions and dry powder inhalers for performing the methods of the invention are also provided.

The present invention provides an inhalable nicotine dry powder composition comprising nicotine powder and fragrance powder, wherein the nicotine powder comprises nicotine or a nicotine salt, amino acids, and excipients, the fragrance powder comprises flavoring agents and excipients, and the nicotine content is less than 0.5% by weight of the total dry powder composition, and a method for producing the same.

The present invention in general relates to a pharmaceutical formulation, specifically a dry powder inhalation formulation for treatment of Corona virus disease-19 (COVID-19). The formulation comprises of combination of an antiviral and a corticosteroid. The invention further describes the method of preparation of the dry powder inhalation formulation.

To provide a dry powder inhalation formulation and its use for therapeutic treatment of lungs.SOLUTION: A dry powder inhalation formulation comprises at least one active pharmaceutical ingredient (API) and a lipid matrix comprising at least one triglyceride selected from the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin, and their mixture. The lipid matrix is hydrogenated castor oil. The ratio between the at least one API and the hydrogenated castor oil is from 10 / 90 to 88 / 12.SELECTED DRAWING: Figure 2

This invention relates to the technical field of dry powder inhaler granulation equipment, specifically to a dry granulation and filling device, comprising a frame, a feeding device, a scraper screen device, a vibrating spheroidizing device, a filtering screen device, and a metering and filling device. The feeding device, scraper screen device, vibrating spheroidizing device, filtering screen device, and metering and filling device are supported by the frame and arranged sequentially along the flow direction of the granular material. The feeding device is fixedly mounted on one side of the frame. The scraper screen device is located on one side of the feeding device and fixed to the frame. One end of the vibrating spheroidizing device is located below the discharge port of the scraper screen device, and the other end is located above the filtering screen device, and both are fixed to the frame. The filtering screen device is located below the discharge port of the vibrating spheroidizing device and fixed to the frame. The metering and filling device is located below the discharge port of the filtering screen device and is fixedly connected to the frame. This invention achieves continuous production by coordinating the various devices, thus improving production efficiency.

This invention discloses a method for preparing a bumetanide nasal administration formulation and its application in the treatment of epilepsy, belonging to the field of pharmaceutical technology. The nasal administration formulation is a bumetanide nasal spray and / or a bumetanide dry powder inhaler. The drug is used for immediate administration intervention within 30 minutes after an epileptic seizure in non-medical settings, including at home, outdoors, or during transport. In this invention, the bumetanide nasal spray or dry powder inhaler does not require intravenous puncture or operation by professional medical personnel. Patients or their families can administer the drug directly through the nasal cavity within 30 minutes after an epileptic seizure at home, outdoors, or during transport, breaking through the dependence of traditional intravenous injection on medical settings and equipment, and buying valuable time for neuronal resuscitation.